MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians. The company was founded in 1979 and is based in Sunrise, Florida.
IPO Year:
Exchange: NYSE
Website: mednax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
| 6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
| 2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
| 12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
| 11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
| 9/27/2021 | $29.00 | Market Perform | SVB Leerink |
| 8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
| 6/23/2021 | $30.00 | Hold | Stifel |
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
3 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 6, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2024. A detailed press release will be issued the morning of August 6, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Pediatrix Medical Group, Inc. (NYSE:MD) is scheduled to present at the following healthcare conferences: May 30, 2024 at 9:20 am CT at the Leerink Partners Healthcare Crossroads Conference in Austin, TX. June 6, 2024 at 7:30 am ET at the Jefferies Global Healthcare Conference in New York, NY. A link to the audio webcasts will be made available at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is one of the nation's leading providers of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children ac
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings of $0.05 per share for the three months ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: Net revenue of $495 million; Net income of $4 million; and Adjusted EBITDA of $37 million. "Our first quarter operating results were in line with our expectations," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our key priorities for 2024 are sharply focused on operating efficiency and stabiliz
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2024. A detailed press release will be issued the morning of May 7, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and c
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $1.50 per share for the three months ended December 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.32. For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: Net revenue of $496 million; Loss from continuing operations of $124 million; and Adjusted EBITDA of $51 million. "Our fourth quarter operating results were consistent with our expectations," said James D. Swift, M.D., Chief Executive Officer of
High preterm birth rate underscores the importance of continuing education on the care of premature and critically ill newborns Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, will host the top meetings in neonatal-perinatal medicine Feb. 19-24 in Las Vegas, Nevada. Specialty Review in Neonatology and NEO: The Conference for Neonatology will take place concurrently, each addressing many of the most critical and controversial issues that influence the clinical practice of neonatal-perinatal medicine today. The meetings will host more than 600 combined attendees comprising neonatologists, neonatology fe
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, February 20, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2023. A detailed press release will be issued the morning of February 20, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to wome
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Friday, November 1, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2024. A detailed press release will be issued the morning of November 1, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and ch
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34. For the 2024 second quarter, Pediatrix reported the following results: Net revenue of $504 million; Net loss of $153 million; and Adjusted EBITDA of $58 million. "Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our previously discussed portfolio management plans are well un
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 6, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2024. A detailed press release will be issued the morning of August 6, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings of $0.05 per share for the three months ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: Net revenue of $495 million; Net income of $4 million; and Adjusted EBITDA of $37 million. "Our first quarter operating results were in line with our expectations," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "Our key priorities for 2024 are sharply focused on operating efficiency and stabiliz
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2024. A detailed press release will be issued the morning of May 7, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and c
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $1.50 per share for the three months ended December 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.32. For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: Net revenue of $496 million; Loss from continuing operations of $124 million; and Adjusted EBITDA of $51 million. "Our fourth quarter operating results were consistent with our expectations," said James D. Swift, M.D., Chief Executive Officer of
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, February 20, 2024 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2023. A detailed press release will be issued the morning of February 20, 2024 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to wome
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.26 per share for the three months ended September 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.32. For the 2023 third quarter, Pediatrix reported the following results from continuing operations: Net revenue of $507 million; Income from continuing operations of $21 million; and Adjusted EBITDA of $50 million. "We believe the underlying fundamentals of our business remain strong, however, the third quarter was more challenged than expect
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, November 2, 2023 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2023. A detailed press release will be issued the morning of November 2, 2023 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to wome
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
SC 13D/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)
Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously
Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00
Credit Suisse reiterated coverage of Mednax with a rating of Outperform and set a new price target of $31.00 from $32.00 previously
Credit Suisse reiterated coverage of Mednax with a rating of Outperform and set a new price target of $32.00 from $33.00 previously
SVB Leerink reiterated coverage of Mednax with a rating of Market Perform and set a new price target of $27.00 from $29.00 previously
SVB Leerink initiated coverage of Mednax with a rating of Market Perform and set a new price target of $29.00
Mizuho reiterated coverage of Mednax with a rating of Neutral and set a new price target of $32.00 from $30.00 previously
Stifel resumed coverage of MEDNAX with a rating of Hold and set a new price target of $30.00
Citigroup reiterated coverage of Mednax with a rating of Neutral and set a new price target of $34.00 from $22.00 previously
Deutsche Bank reiterated coverage of Mednax with a rating of Sell and set a new price target of $24.00 from $17.50 previously
Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu
PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof
Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:MD) with a Hold and lowers the price target from $10 to $8.
Deutsche Bank analyst Pito Chickering upgrades Pediatrix Medical Group (NYSE:MD) from Sell to Hold and maintains the price target from $8 to $8.
In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:MD), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 3 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has
Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:MD) with a Hold and maintains $10 price target.
Pediatrix Medical Group (NYSE:MD) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is a 13.04 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $495.10 million which missed the analyst consensus estimate of $499.08 million by 0.80 percent. This is a 0.83 percent increase over sales of $491.01 million the same period last year.
Jefferies analyst Brian Tanquilut maintains Pediatrix Medical Group (NYSE:MD) with a Hold and lowers the price target from $10 to $9.
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. • Fresenius Medical Care (NYSE:FMS) is projected to report quarterly earnings at $0.32 per share on revenue of $5.35 billion. • NexPoint Residential (NYSE:NXRT) is projected to report earnings for its fourth quarter. • Summit Therapeutics (NASDAQ:SMMT) is likely to report earnings for its fourth quarter. • Axsome Therapeutics (NASDAQ:AXSM) is projected to report quarterly loss at $1.15 per share on revenue of $67.69 million. • Gran Tierra Energy (AMEX:GTE) is expected to report quarterly loss at $0.13 per share on revenue of $60 thousand. • O
Pediatrix Medical Group (NYSE:MD) reported its Q4 earnings results on Tuesday, February 20, 2024 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Pediatrix Medical Group reported in-line EPS of $0.32 versus an estimate of $0.32. Revenue was down $17.40 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.11 which was followed by a 0.1% increase in the share price the next day. Here's a look at Pediatrix Medical Group's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate 0.43 0.39 0.23 0.48 EPS Actual 0.32 0.39 0.23 0.47 Revenue Estimate 508.25M 494.47M 490.78M 501.99M Rev